Hematologic manifestations of malignancy

Robert A. Johnson, G. David Roodman

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Hematologic dysfunction occurs commonly in patients with malignancy. Over half are anemic, often because of acute or chronic blood loss, marrow involvement by the malignancy, marrow suppressive effects of chemotherapy or radiation therapy, or because of the anemia of chronic disease. Less frequently, anemia may result from red cell aplasia, folate or B12 deficiency, hemolytic processes, or hypersplenism. Occasional patients may become polycythemic because of erythropoietin-producing tumors such as renal adenocarcinomas or cerebellar hemangiomas. Elevation of the white cell count is commonly seen, especially in patients with lung cancer. Monocytosis and thrombocytosis, which may be early signs of an underlying malignancy, are also very common and occur in up to half of patients. Thrombocytopenia is commonly a result of therapy or marrow replacement; a few patients may have a syndrome resembling immune thrombocytopenic purpura. Abnormalities of coagulation are present in many patients, and may lead to superficial or deep venous thromboses, pulmonary emboli, nonbacterial thrombotic endocarditis with arterial emboli, bleeding, or acute disseminated intravascular coagulation. A sound understanding of the potential hematologic complications that can result from the malignant process is essential to the clinician caring for cancer patients.

Original languageEnglish (US)
Pages (from-to)726-768
Number of pages43
JournalDisease-a-Month
Volume35
Issue number11
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Hematologic Neoplasms
Bone Marrow
Neoplasms
Embolism
Anemia
Hypersplenism
Thrombocytosis
Idiopathic Thrombocytopenic Purpura
Disseminated Intravascular Coagulation
Hemangioma
Erythropoietin
Endocarditis
Renal Cell Carcinoma
Folic Acid
Venous Thrombosis
Thrombocytopenia
Lung Neoplasms
Chronic Disease
Radiotherapy
Cell Count

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hematologic manifestations of malignancy. / Johnson, Robert A.; Roodman, G. David.

In: Disease-a-Month, Vol. 35, No. 11, 1989, p. 726-768.

Research output: Contribution to journalArticle

Johnson, Robert A. ; Roodman, G. David. / Hematologic manifestations of malignancy. In: Disease-a-Month. 1989 ; Vol. 35, No. 11. pp. 726-768.
@article{d16123ab27944272ac19565d1fdbbd6d,
title = "Hematologic manifestations of malignancy",
abstract = "Hematologic dysfunction occurs commonly in patients with malignancy. Over half are anemic, often because of acute or chronic blood loss, marrow involvement by the malignancy, marrow suppressive effects of chemotherapy or radiation therapy, or because of the anemia of chronic disease. Less frequently, anemia may result from red cell aplasia, folate or B12 deficiency, hemolytic processes, or hypersplenism. Occasional patients may become polycythemic because of erythropoietin-producing tumors such as renal adenocarcinomas or cerebellar hemangiomas. Elevation of the white cell count is commonly seen, especially in patients with lung cancer. Monocytosis and thrombocytosis, which may be early signs of an underlying malignancy, are also very common and occur in up to half of patients. Thrombocytopenia is commonly a result of therapy or marrow replacement; a few patients may have a syndrome resembling immune thrombocytopenic purpura. Abnormalities of coagulation are present in many patients, and may lead to superficial or deep venous thromboses, pulmonary emboli, nonbacterial thrombotic endocarditis with arterial emboli, bleeding, or acute disseminated intravascular coagulation. A sound understanding of the potential hematologic complications that can result from the malignant process is essential to the clinician caring for cancer patients.",
author = "Johnson, {Robert A.} and Roodman, {G. David}",
year = "1989",
doi = "10.1016/0011-5029(89)90011-4",
language = "English (US)",
volume = "35",
pages = "726--768",
journal = "Disease-a-Month",
issn = "0011-5029",
publisher = "Mosby Inc.",
number = "11",

}

TY - JOUR

T1 - Hematologic manifestations of malignancy

AU - Johnson, Robert A.

AU - Roodman, G. David

PY - 1989

Y1 - 1989

N2 - Hematologic dysfunction occurs commonly in patients with malignancy. Over half are anemic, often because of acute or chronic blood loss, marrow involvement by the malignancy, marrow suppressive effects of chemotherapy or radiation therapy, or because of the anemia of chronic disease. Less frequently, anemia may result from red cell aplasia, folate or B12 deficiency, hemolytic processes, or hypersplenism. Occasional patients may become polycythemic because of erythropoietin-producing tumors such as renal adenocarcinomas or cerebellar hemangiomas. Elevation of the white cell count is commonly seen, especially in patients with lung cancer. Monocytosis and thrombocytosis, which may be early signs of an underlying malignancy, are also very common and occur in up to half of patients. Thrombocytopenia is commonly a result of therapy or marrow replacement; a few patients may have a syndrome resembling immune thrombocytopenic purpura. Abnormalities of coagulation are present in many patients, and may lead to superficial or deep venous thromboses, pulmonary emboli, nonbacterial thrombotic endocarditis with arterial emboli, bleeding, or acute disseminated intravascular coagulation. A sound understanding of the potential hematologic complications that can result from the malignant process is essential to the clinician caring for cancer patients.

AB - Hematologic dysfunction occurs commonly in patients with malignancy. Over half are anemic, often because of acute or chronic blood loss, marrow involvement by the malignancy, marrow suppressive effects of chemotherapy or radiation therapy, or because of the anemia of chronic disease. Less frequently, anemia may result from red cell aplasia, folate or B12 deficiency, hemolytic processes, or hypersplenism. Occasional patients may become polycythemic because of erythropoietin-producing tumors such as renal adenocarcinomas or cerebellar hemangiomas. Elevation of the white cell count is commonly seen, especially in patients with lung cancer. Monocytosis and thrombocytosis, which may be early signs of an underlying malignancy, are also very common and occur in up to half of patients. Thrombocytopenia is commonly a result of therapy or marrow replacement; a few patients may have a syndrome resembling immune thrombocytopenic purpura. Abnormalities of coagulation are present in many patients, and may lead to superficial or deep venous thromboses, pulmonary emboli, nonbacterial thrombotic endocarditis with arterial emboli, bleeding, or acute disseminated intravascular coagulation. A sound understanding of the potential hematologic complications that can result from the malignant process is essential to the clinician caring for cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0024757265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024757265&partnerID=8YFLogxK

U2 - 10.1016/0011-5029(89)90011-4

DO - 10.1016/0011-5029(89)90011-4

M3 - Article

C2 - 2680358

AN - SCOPUS:0024757265

VL - 35

SP - 726

EP - 768

JO - Disease-a-Month

JF - Disease-a-Month

SN - 0011-5029

IS - 11

ER -